← FDA DRUG APPROVALS

FDA NDA · NDA009838

RESERPINE

Sponsor: SANDOZ

APPLICATION
NDA009838
TYPE
NDA
ORIGINAL APPROVAL
1955-03-24
LATEST ACTION
2015-06-17
ROUTE
ORAL
DOSAGE FORM
TABLET
MARKETING STATUS
Discontinued

Products

RESERPINE · ReferenceDiscontinued
RESERPINE 0.25MG · TABLET · ORAL
RESERPINE · ReferenceDiscontinued
RESERPINE 0.1MG · TABLET · ORAL

Approval history

2015-06-17Manufacturing (CMC) · Supplement 40AP
1999-12-08Manufacturing (CMC) · Supplement 35AP
1999-09-07Manufacturing (CMC) · Supplement 34AP
1996-11-06Labeling · Supplement 33 · standardAP
1996-03-15Manufacturing (CMC) · Supplement 32AP
1955-03-24Type 5 - New Formulation or New Manufacturer · Original · standardAP
VIEW ON DRUGS@FDA ↗

Related on SPEQ

Pharma industryGMP disciplineFDA drug shortagesFDA enforcement & recalls

Source: FDA Drugs@FDA. SPEQ is not affiliated with the FDA; this is a reference view of public FDA data, not medical, legal, or regulatory advice.

Weekly Briefing

Get the Weekly GxP Briefing

Curated regulatory intelligence — enforcement, recalls, guidance, and quality signals — in one practitioner-grade email each week. Free.

Read a past issue →